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The	molecular	basis	of	the	interactions	between	synthetic	retinoic	
acid	analogues	and	the	retinoic	acid	receptors	
Hesham	Haffez,a,b,c,d	David	R.	Chisholm,a	Roy	Valentine,e	Ehmke	Pohl,b	Christopher	Redfernc	and	
Andrew	Whitinga	
All-trans-retinoic	 acid	 (ATRA)	 and	 its	 synthetic	 analogues	 EC23	 and	 EC19	direct	 cellular	 differentiation	 by	 interacting	 as	
ligands	 for	 the	 retinoic	 acid	 receptor	 (RARα,	β	 and	 γ)	 family	of	 nuclear	 receptor	proteins.	 To	date,	 a	number	of	 crystal	
structures	of	natural	and	synthetic	ligands	complexed	to	their	target	proteins	have	been	solved,	providing	molecular	level	
snap-shots	 of	 ligand	 binding.	 However,	 a	 deeper	 understanding	 of	 receptor	 and	 ligand	 flexibility	 and	 conformational	
freedom	is	required	to	develop	stable	and	effective	ATRA	analogues	for	clinical	use.	Therefore,	we	have	used	molecular	
modelling	techniques	to	define	RAR	interactions	with	ATRA	and	two	synthetic	analogues,	EC19	and	EC23,	and	compared	
their	 predicted	 biochemical	 activities	 to	 experimental	 measurements	 of	 relative	 ligand	 affinity	 and	 recruitment	 of	
coactivator	proteins.	A	comprehensive	molecular	docking	approach	that	explored	the	conformational	space	of	the	ligands	
indicated	 that	ATRA	 is	 able	 to	bind	 the	 three	RAR	proteins	 in	 a	number	of	 conformations	with	one	extended	 structure	
being	 favoured.	 In	 contrast	 the	 biologically-distinct	 isomer,	 9-cis-retinoic	 acid	 (9CRA),	 showed	 significantly	 less	
conformational	flexibility	in	the	RAR	binding	pockets.	These	findings	were	used	to	inform	docking	studies	of	the	synthetic	
retinoids	 EC23	 and	 EC19,	 and	 their	 respective	methyl	 esters.	 	 EC23	was	 found	 to	 be	 an	 excellent	mimic	 for	ATRA,	 and	
occupied	 similar	 binding	modes	 to	ATRA	 in	 all	 three	 target	 RAR	proteins.	 In	 comparison,	 EC19	 exhibited	 an	 alternative	
binding	mode	which	reduces	the	strength	of	key	polar	interactions	in	RARα/γ	but	is	well-suited	to	the	larger	RARβ	binding	
pocket.	In	contrast,	docking	of	the	corresponding	esters	revealed	the	loss	of	key	polar	interactions	which	may	explain	the	
much	reduced	biological	activity.	Our	computational	results	were	complemented	using	an	in	vitro	binding	assay	based	on	
FRET	 measurements,	 which	 showed	 that	 EC23	 was	 a	 strongly	 binding,	 pan-agonist	 of	 the	 RARs,	 while	 EC19	 exhibited	
specificity	for	RARβ,	as	predicted	by	the	docking	studies.	These	findings	can	account	for	the	distinct	behaviour	of	EC23	and	
EC19	 in	 cellular	 differentiation	 assays,	 and	 additionally,	 the	 methods	 described	 herein	 can	 be	 further	 applied	 to	 the	
understanding	of	the	molecular	basis	for	the	selectivity	of	different	retinoids	to	RARα,	β	and	γ.		
Introduction	
All-trans-retinoic	acid	(ATRA),	the	major	metabolite	of	vitamin	
A,	 has	 essential	 roles	 in	 many	 biological	 processes	 during	
embryogenesis	 and	 homeostasis	 in	 chordates,	 including	 cell	
differentiation,	 proliferation	 and	 apoptosis,	 embryonic	
development	 and	 vision.1,2	 Due	 to	 this	 powerful	 and	 wide	
ranging	 biological	 activity,	 ATRA	 and	 its	 isomers	 have	 been	
used	as	therapeutics	for	the	treatment	of	various	cancers	and	
skin	conditions.3,4	In	addition,	ATRA	is	routinely	used	in	vitro	as	
an	 inducer	 of	 cellular	 differentiation;	 however,	 its	 usage	 has	
limitations,	as	the	compound	readily	isomerises	to	mixtures	of	
ATRA,	 9-cis-retinoic	 acid	 (9CRA),	 13-cis-retinoic	 acid	 (13CRA)	
and	 other	 species.5,6	 This	 instability	 is	 derived	 from	 the	 five	
conjugated	 double	 bonds	 that	 absorb	 visible	 light	 at	
wavelengths	of	300-400	nm.	In	addition,	ATRA	is	inactivated	in	
vivo	 by	 inducible	 and	 constitutively	 expressed	 cytochrome	
P450	enzymes.7,8	While	9CRA	may	also	have	a	cellular	role	as	a	
ligand	to	activate	transcription	factors,	a	natural	physiological	
function	 for	 13CRA	 as	 a	 transcription-factor	 ligand	 is	 less	
certain.5		
	 We	 have	 previously	 described	 two	 light-stable	 synthetic	
retinoid	 analogues,	 EC23	 and	 EC19	 (Figure	 1,	 left),9	 differing	
from	 each	 other	 only	 in	 the	 position	 of	 the	 carboxylic	 acid	
group	on	the	terminal	substituted	ring.	EC23	was	designed	to	
mimic	 ATRA,	 whereas	 the	 meta-position	 carboxylic	 acid	 of	
EC19	 changes	 the	 effective	 geometry	 of	 the	 molecule	 in	 a	
similar	 manner	 to	 the	 alkene	 geometry	 differences	 between	
ATRA	and	13CRA.	Previous	studies	showed	that	EC23	 induced	
neuronal	differentiation	in	pluripotent	stem	cells	at	a	lower			
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Figure	 1:	 Left,	 chemical	 structures	 of	 endogenous	 retinoids	 ATRA	 and	 9CRA,	 synthetic	 retinoids	 EC23	 and	 EC19,	 and	 synthetic	 retinoid	 esters	 EC23Me	 and	 EC19Me.3,9	 Right,	
proposed	investigation	into	the	interactions	of	natural	and	synthetic	retinoids	by	combining	in	silico	docking	studies	with	an	in	vitro	binding	assay.	
concentration	than	ATRA,	whereas,	EC19	facilitated	epithelial-
like	development,	rather	than	neuronal	differentiation.9	Thus,	
although	 EC23	 and	 EC19	 are	 chemically	 similar,	 they	 have	
substantially	different	biological	effects.		
The	 biological	 activity	 of	 ATRA	 is	 the	 result	 of	 its	
interactions	with	the	retinoic	acid	receptors	(RARs),	which	are	
ligand-dependent,	 transcriptional	 regulators.	 Three	 closely	
related	isotypes,	designated	RARα,	RARβ	and	RARγ,	have	been	
identified	in	vertebrates.2,10,11	The	interaction	of	ATRA	with	the	
ligand-binding	 domain	 (LBD)	 of	 these	 receptors	 results	 in	
conformational	 changes,	 particularly	 with	 respect	 to	 the	 C-
terminal	 helix	 12	 (H12,	 shown	 in	 red	 in	 Figure	 1),	 which	
facilitates	 recruitment	of	 transcriptional	 co-activators,	 leading	
to	DNA	binding	and	hence	gene	activation.11,12	Essentially,	the	
retinoid	 enters	 the	 ligand	 binding	 pocket	 of	 the	 RAR	 LBD,	
guided	 by	 an	 electrostatic	 gradient	 generated	 by	 a	 cluster	 of	
polar	 residues	 including	 a	 positively	 charged	 arginine	 at	 the	
bottom	of	 the	 pocket.13	 The	 carboxylate	 of	 the	 retinoid	 then	
associates	with	this	polar	cluster,	anchoring	the	retinoid	inside	
the	pocket,	whereupon	H12	 is	 thought	 to	 swing	around	 from	
its	solvent	exposed	apo-position	to	close	the	pocket,	trapping	
the	 retinoid	 inside.13,14	 Previous	 X-ray	 crystal	 structures	 of	
RAR-retinoid	 complexes	 have	 shown	 that	 the	 retinoids	 are	
completely	 buried	 within	 the	 binding	 pocket	 formed	 by	
residues	 from	helices	H3,	H5,	H7	and	H11,	 and	a	β-turn,	 in	 a	
mainly	 α-helical	 binding	 domain.	 The	 majority	 of	 contacts	
within	 the	LBD	are	van	der	Waals	 interactions,	except	 for	 the	
carboxylate	 group	 of	 the	 retinoid	 which	 forms	 a	 salt	 bridge	
with	a	conserved	Arg	residue	from	helix	H5	and	a	network	of	
hydrogen	 bonds	 with	 a	 Ser	 residue	 (β-turn)	 and/or	 Lys	
residues.13,14	 The	 retinoid-bound	 conformation	 provides	 a	
stable	platform	for	the	recruitment	and	binding	of	coactivator	
peptides	 and	dimerization	 to	 the	 related	 retinoid-X-receptors	
(RXR).15–17	
Sequence	 alignment	 of	 RARα,	 β	 and	 γ	 shows	 that	 only	
three	 residues	 in	 the	 binding	 pocket	 are	 variable,	 i.e.	 RARγ	
exhibits	Ala234	(Ser232	in	α	and	Ala225	in	β),	Met272	(Ile270	
in	 α	 and	 Ile263	 in	 β)	 and	 Ala397	 (Val395	 in	 α	 and	 Val388	 in	
β).18,19	 These	 divergent	 residues	 account	 for	 the	 observed	
selectivity	of	the	different	retinoic	acids	towards	binding	with	
RARα,	β	and	γ,	and	have	been	exploited	to	 inform	the	design	
of	a	variety	of	isotype-specific	synthetic	retinoids.3,20,21							
The	second	endogenous	ligand	for	the	RARs	is	9CRA,	a	cis-
isomer	of	ATRA,	which	acts	as	an	agonist	for	both	RARs	and	a	
second	class	of	retinoic	acid	receptor,	the	retinoid	X-receptors,	
(RXR).22–24	Crystallographic	studies	of	the	LBDs	of	both	types	of	
receptor	 show	 that	 although	 the	overall	 architecture	of	RARs	
and	RXRs	is	very	similar,	the	shape	of	the	ligand	binding	pocket	
Journal	Name	 	ARTICLE	
This	journal	is	©	The	Royal	Society	of	Chemistry	20xx	 J.	Name.,	2013,	00,	1-3	|	3 	
Please	do	not	adjust	margins	
Please	do	not	adjust	margins	
differs	 markedly	 between	 RARs	 and	 RXRs.25	 RARs	 possess	 a	
linear	 "I"	 shaped	 pocket,	whereas	 the	 RXRs	 exhibit	 a	 shorter	
and	more	restrictive	"L"	shape.	As	a	result,	the	 linear	retinoid	
ATRA	mainly	acts	as	a	ligand	for	RARs	while	9CRA	exhibits	high	
binding	affinity	for	both	the	RARs	and	RXRs.22,26,27		
Although	EC23	is	more	effective	than	either	ATRA	or	EC19	
in	 differentiation	 assays,9	 cell-based	 biological	 assays	 cannot	
be	 used	 to	 elucidate	 the	 affinities	 of	 synthetic	 retinoids	 for	
RAR	receptor	types	because	the	specificities	of	different	RARs	
as	 drivers	 of	 biological	 responses	 are	 poorly	 understood.	
Therefore,	 the	 molecular	 basis	 of	 the	 ligand-receptor	
interactions	 that	 underpin	 these	 differences	 in	 biological	
activity	 remains	 unclear.	 Transcriptional	 responses	 mediated	
by	 retinoids	 involve	 a	 complex	 series	 of	 events,	 starting	with	
ligand	 binding	 of	 the	 nuclear	 receptor	 and	 leading	 to	 the	
recruitment	of	co-activator	proteins.	It	is,	therefore,	important	
to	understand	the	factors	that	affect	retinoid	binding	to	RARs,	
especially	 as	 a	 function	 of	 the	 chemical	 structure	 and	
conformational	 flexibility	 of	 the	 ligand	 in	 the	 context	 of	 each	
RAR	 type.	 To	 address	 this	 question,	 receptor-binding	 assays	
are	 required	 to	confirm	predictions	 from	structural	modelling	
studies	and	to	explain	how	structural	differences	constrain	the	
biological	activity	of	different	 ligands.	Accordingly,	 the	aim	of	
this	 study	 (Figure	 1,	 right)	 was	 to	 unravel	 the	 molecular	
interactions	of	these	retinoids	with	the	RARs	by	modelling	the	
binding	of	EC23	and	EC19,	and	their	respective	methyl	esters,	
in	comparison	to	ATRA	and	9CRA	to	the	ligand-binding	pocket	
of	 each	 RAR	 isotype,	 and	 to	 compare	 the	 results	 with	
experimental	 measurements	 of	 ligand-receptor	 binding	
interactions.	This	approach	will	enhance	our	understanding	of	
the	molecular	 basis	 of	 retinoid-mediated	 cellular	 activity	 and	
help	 inform	 the	 design	 of	 the	 next	 generation	 of	 synthetic	
retinoids	as	reagents,	therapeutics	and	biological	probes.	
Experimental	
Molecular	Modelling	
Molecular	 structures	 of	 all	 compounds	 (ATRA,	 9CRA,	 EC23,	
EC19,	EC23Me	and	EC19Me)	were	generated	using	Spartan	‘14	
(Wavefunction	 Inc.,	 Irvine,	CA).28	These	were	minimised	using	
a	molecular	mechanics	force	field,	 followed	by	semi-empirical	
molecular	 orbital	 (AM1)	 methods	 to	 generate	 a	 conformer	
distribution	 in	 vacuo.	 The	 generated	 conformations	 of	 each	
compound	 were	 then	 re-minimised	 using	 a	 higher	 level	 of	
theory	 (Hartree-Fock,	 3-21G)	 to	 ensure	 that	 the	 generated	
conformer	 distribution	 was	 realistic.	 All	 possible	
conformations	of	all	compounds	were	saved	as	 .mol2	files	for	
use	in	the	docking	studies.		
	
Docking	
Due	 to	 the	 significant	 conformational	 flexibility	 exhibited	 by	
ATRA	 in	particular,	and	 the	close	energy	differences	between	
the	observed	conformers,	we	were	interested	to	examine	how	
a	docking	simulation	would	interpret	the	binding	process	from	
a	variety	of	starting	points.29	Accordingly,	rather	than	docking	
only	 the	 lowest	 energy	 structures,	 all	 of	 the	 output	
conformations	from	the	conformer	distribution	calculations	of	
ATRA,	9CRA,	EC23,	EC23Me,	EC19	and	EC19Me	were	prepared	
for	docking	using	GOLD.30		
Crystal	 structures	 were	 retrieved	 from	 the	 RCSB	 protein	
data	bank	as	PDB	files	(3KMR31	for	RARα,	1XAP20	for	RARβ	and	
2LBD13	 for	RARγ).	 The	bound	 ligands	were	 removed	 from	 the	
structures,	and	used	only	as	a	positional	 reference.	Hydrogen	
atoms	were	added	to	protein	residues	using	the	default	GOLD	
settings30.	 All	 solvent	 molecules	 were	 removed.	 Active	 site	
residues	were	 selected	within	 a	 diameter	 of	 15	 Å,	measured	
from	a	selected	point	at	the	centre	of	the	ligand	position,	and	
therefore	included	the	entire	binding	pocket.	It	is	important	to	
note	 that	 the	 carboxylic	 acid	 moiety	 was	 considered	 as	 a	
carboxylate,	 rather	 than	 protonated,	 as	 this	 is	 more	 realistic	
with	respect	to	physiological	pH,	and	to	the	likelihood	that	the	
negative	 charge	 is	 stabilised	 by	 the	 closely	 positioned	 polar	
residues	 in	 the	binding	pocket.15,32	ChemScore	was	chosen	as	
the	most	appropriate	target	 function	 in	the	genetic	algorithm	
to	balance	between	computational	speed	and	the	reliability	of	
the	 GOLD	 predictions	 for	 the	 possible	 conformations	 of	 the	
different	 retinoids	 binding	 to	 RARs.33	 The	 genetic	 algorithm	
parameters	 were	 based	 on	 previous	 examples	 of	 docking	
hydrophobic	ligands:	population	size	100;	number	of	islands	5;	
niche	size	2;	selection	pressure	1.1;	migrate	2;	and	number	of	
operators	 100,000.34	 A	 search	 efficiency	 of	 200%	 was	 used,	
which	 dictates	 maximum	 ligand	 flexibility.	 Ligands	 were	 also	
allowed	 maximum	 flexibility.	 During	 the	 docking	 process	 no	
limit	 was	 placed	 on	 the	 number	 of	 binding	 poses	 retained,	
though	 typically	 3-10	 solutions	 were	 retained	 by	 the	 genetic	
algorithm.		
	
In	vitro	binding	assay	
The	binding	 interactions	of	ATRA,	9CRA,	EC23,	EC23Me,	EC19	
and	EC19Me	with	RARα,	β	and	γ	were	determined	 in	vitro	by	
time-resolved	 fluorescence	 resonance	 energy	 transfer	 (TR-
FRET)35	using	the	LanthaScreen	TR-FRET	RARα,	RARβ,	and	RARγ	
co-activator	 assays	 according	 to	 the	 manufacturer’s	
(InvitrogenTM)	 instructions.	 This	 uses	 a	 terbium-labelled	 anti-
GST	 antibody,	 a	 fluorescein-labelled	 coactivator	 peptide,	 and	
RARα,	 β	 or	 γ	 ligand-binding	 domains	 fused	 to	 glutathione-S-
transferase	 (GST)	 in	 a	 homogenous	 assay	 format.	 All	
experiments	 were	 performed	 in	 black,	 384-well	 low-volume	
plates	 in	the	dark	at	room	temperature	with	a	4	h	 incubation	
time.	The	final	assay	volume	was	20	μL	and	all	dilutions	were	
carried	 out	 using	 TR-FRET	 assay	 buffer,	 with	 a	 final	 DMSO	
concentration	 of	 1%.	 A	 mixture	 of	 either	 3.5	 nM	 GST-RARα-
LBD	or	2.5	nM	GST-RARβ-LBD	or	3	nM	GST-RARγ-LBD	with	62.5	
nM	Tb-anti	GST	antibody,	 30	µM	 fluorescein-labelled	peptide	
(Fluorescein-D22,	 Fluorescein-SRC2-2	 and	 Fluorescein-PGC1a	
for	 RAR-α,	 RAR-β,	 and	 RAR-γ	 respectively),	 and	 retinoid	 or	
DMSO	 control	 was	 added	 to	 each	 of	 the	 wells.	 Each	 ligand	
assay	 was	 performed	 in	 duplicate	 and	 measured	 using	 a	
PHERAstar	 FS	Microplate	 Reader	 (BMG	 Labtech,	 Ortenberg,	
Germany)	 with	 instrument	 settings	 as	 described	 in	 the	
manufacturer’s	 instructions	 for	 LanthaScreen	 assays.	 The	 TR-
FRET	signal	was	expressed	as	the	ratio	of	the	signals	at	520	nm	
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and	490	nm.	The	data	were	fitted	to	a	three-parameter	ligand-
binding	 curve	 using	 SigmaPlot	 (version	 12.5,	 Systat	 Software	
Inc.,	 San	 Jose	 CA)	 and	 normalized	 to	 the	 lower	 asymptote	 of	
each	 binding	 curve.	 The	 TR-FRET	 binding	 assay	 produces	
sigmoidal	 curves	 with	 different	 mid-point	 (EC50)	 and	 upper	
asymptote.	 Since	 the	 assay	 involves	 interactions	 between	
ligand	 and	 LBD,	 and	 ligand-dependent	 interactions	 between	
the	LBD	and	fluorescein-labelled	coactivator,	the	binding	assay	
data	 were	 interpreted	 by	 reference	 to	 simulations	 of	 these	
coupled	 chemical	 reactions	 using	 the	 biochemical	 simulator	
COPASI	version	4.3.36	
	
Results	and	Discussion	
Molecular	modelling	and	docking	
From	 the	 conformation	 studies,	 it	 was	 found	 that	 ATRA	 and	
9CRA	 exhibited	 a	 range	 of	 accessible	 low	 energy	
conformations,	 all	 within	 around	 3-5	 kcal/mol,	 while	 the	
synthetic	retinoids	EC23,	EC19,	EC23Me	and	EC19Me	exhibited	
between	 1-4	 conformations	 (see	 ESI	 for	 further	 detail	 on	 all	
calculated	 conformations).	 For	 ATRA,	 the	 presence	 of	 the	
methyl	groups	on	the	cyclohexenyl	ring	resulted	in	low	energy	
conformations	 in	 which	 the	 conjugated	 polyene	 was	 twisted	
out	of	plane	with	the	6-membered	ring.	An	all	s-trans-polyene	
configuration	 for	 ATRA	 was	 found	 as	 the	 lowest	 energy	
conformation,	which	was	within	1	kJ/mol	of	the	second	lowest	
general	structure,	in	which	ATRA	adopted	one	s-cis	sigma-bond	
rotation	 (C8=C9)	 in	 the	 middle	 of	 the	 polyene,	 apparently	
relieving	strain	due	to	the	presence	of	the	C7	methyl	group.	All	
low	 energy	 conformations	 for	 ATRA	 showed	 an	 out-of-plane	
twisting	 of	 the	 polyene	 from	 the	 plane	 of	 the	 cyclohexenyl	
ring,	 especially	 the	 endo-cyclic	 alkene.29,37	 Otherwise,	 the	
conformations	 only	 differed	 in	 terms	 of	 which	 sigma	 bonds	
exhibited	 s-cis	 conformations	 (see	 SI	 for	 structures).	 The	
difference	 in	 energy	 between	 the	 lowest	 and	 highest	 energy	
conformations	was	 only	 around	 15	 kJ/mol	 and	 hence,	 all	 are	
selectable	 as	 possible	 structures	 that	 could	 bind	 to	 the	
receptor	 sites	 since	 all	 such	 conformations	 would	 exist	 in	
similar	 amounts	 in	 solution	 at	 RT	 and	 physiological	
temperature.		
For	9CRA,	the	 lowest	energy	conformation	showed	similar	
trends	 to	 that	of	ATRA,	with	 the	polyene	section	 twisting	out	
of	 plane	 from	 the	 cyclohexenyl	 ring	 due	 to	 steric	 repulsion	
with	 the	 6-ring	 geminal	 dimethyl	 groups	 (C7	 in	 particular);	
similar	 s-cis	 sigma	 bond	 rotational	 effects	were	 also	 present.	
The	 difference	 between	 the	 lowest	 and	 highest	 energy	
conformations	was	 again	 only	 around	 19	 kJ/mol.	 EC23,	 EC19	
and	 their	 respective	methyl	 esters	 displayed	 significantly	 less	
conformational	 flexibility	 as	 expected	 due	 to	 their	 more	
restrained	 chemical	 structures	 and	 particularly	 the	 linear	
alkyne	motif.	 In	 EC23,	 for	 example,	 the	 plane	 of	 the	 benzoic	
acid	 polar	 region	 was	 perpendicular	 with	 respect	 to	 the	
tetrahydronaphthalene	 hydrophobic	 region.	 In	 EC23Me	 two	
low	 energy	 structures	 were	 obtained	 with	 each	 exhibiting	
opposing	 ring	 conformations	 for	 the	 tetrahydronaphthalene	
ring.	 Only	 one	 solution	 was	 returned	 for	 EC23	 and	 EC19,	
suggesting	 that	 the	 energy	 difference	 between	 the	 relative	
orientations	of	the	two	rings	was	negligible.		
After	 the	possible	 starting	 conformations	of	 each	 retinoid	
were	 docked	 into	 the	 RARs,	 each	 solution	 was	 examined	
before	 further	 analysis,	 to	 ensure	 that	 the	 archetypal	
positioning	 of	 the	 retinoid	 ligand	 according	 to	 the	 existing	
literature	 crystal	 structures	 was	 correctly	 occupied.	 The	 vast	
majority	of	solutions	satisfied	this	criterion,	though	in	the	case	
of	 9CRA	 some	 solutions	 indicated	 atypical	 poses,	 and,	
accordingly,	 exhibited	 significantly	 lower	 fitness	 scores;	 these	
solutions	were	discarded	 from	further	analysis.	Solutions	 that	
exhibited	the	expected	position	were	close	in	fitness	score	(+/-	
1.5	fitness	score).	Each	binding	pose	was	then	extracted	from	
the	protein	structure,	and	individually	examined	to	assign	and	
assess	its	conformation.	Importantly,	these	binding	poses	were	
independent	of	the	starting	conformation	(by	inspection),	thus	
indicating	 that	 the	 docking	 protocol	 sampled	 the	
conformational	 space	 sufficiently	 and	 predicts	 binding	 poses	
that	 were	 determined	 by	 the	 structure	 of	 the	 RAR	 binding	
pockets.	 Due	 to	 their	 low	 conformational	 flexibility,	 the	
docking	 solutions	 of	 EC23,	 EC23Me,	 EC19	 and	 EC19Me	
exhibited	 only	 minor	 differences	 between	 different	 binding	
poses,	 principally	 in	 the	 angle	 between	 the	 plane	 of	 the	
tetrahydronaphthalene	hydrophobic	region	with	respect	to	the	
plane	 of	 the	 benzoate/benzoic	 acid	 polar	 region.	 9CRA	
exhibited	only	two	conformations	(Figure	2)	with	the	expected	
9-cis	 polyene	 structure	with	 two	 possible	 orientations	 of	 the	
cyclohexenyl	 ring.37	 In	 contrast,	 analysis	 of	 the	 docking	
solutions	 of	 ATRA	 identified	 eleven	 possible	 binding	
conformations.	To	gain	 further	 insight	 into	 the	distribution	of	
these	 conformations	 and	 to	 ascertain	 whether	 a	 particular	
conformation	 was	 favoured,	 a	 clustering	 approach	 was	
developed	whereby	each	docking	pose	of	ATRA	and	9CRA	was	
individually	 examined	 and	 assigned	 to	 a	 particular	
conformation,	 and	 the	 percentage	 incidence	 of	 each	 was	
plotted	 for	 each	 RAR	 as	 a	 histogram	 in	 Figures	 2-3.	
Conformations	1,	2	and	7	were	 the	most	 frequently	obtained	
by	GOLD.	 Furthermore,	 conformation	 1	was	 found	 at	 around	
double	the	frequency	of	conformations	2	and	7.	 Interestingly,	
conformation	 1	 was	 only	 the	 second	 lowest	 energy	
conformation	 according	 to	 the	 initial	 conformer	 distribution	
calculations	 (conformation	 7	 was	 the	 lowest	 energy),	
indicating	that	GOLD	correctly	attempted	to	fit	the	most	suited	
conformation	 to	 the	shape	of	 the	binding	pocket	and	did	not	
simply	bind	the	lowest	energy	conformation.	The	less	sampled	
conformations	 were	 also	 those	 conformations	 with	 higher	
energy	 in	 the	 initial	 conformational	 distribution	 calculations.	
These	observations	 further	highlighted	 the	 fine	differences	 in	
energy	between	each	of	 the	possible	conformations	of	ATRA,	
and	 initially	 indicated	 that	 ATRA	 likely	 binds	 in	 a	 variety	 of	
conformations,	although	one	may	be	 favoured	 in	particular.38	
To	 confirm	 that	 the	 less-frequently	 sampled	 conformations	
were	 not	 simply	 derived	 from	 solutions	 that	 had	 not	
completely	converged,	examples	of	each	docked	conformation	
was	 extracted	 from	 the	 protein	 structure	 and	 docked	 again,	
further	analysis	of	the	distribution	of	binding	poses	in	Figure	3	
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indicated	 that	 the	 range	 of	 obtained	 conformations	 agreed	
with	the	known	shapes	and	structures	of	the	respective	RARα,	
β	 and	 γ	 binding	 sites.	 For	 example,	 docking	 ATRA	 into	 the	
larger	 pocket	 of	 RARβ	 resulted	 in	 a	 much	 greater	 range	 of	
conformations	 than	 the	 slightly	 smaller,	 thinner	 pockets	 of	
RARα	 and	 RARγ.20,39	 This	 suggests	 that	 the	 RARβ	 pocket	was	
also	 able	 to	 select	 the	 less	 linear	 conformations,	 such	 as	
conformations	 4,	 6	 and	 10.	 RARα	 and	 RARγ	 mainly	
accommodated	 the	 more	 linear	 conformations,	 such	 as	
conformation	1,	2	and	7,	during	the	docking	process.	
		
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	 2:	 (Left)	 The	 conformations	 of	 9CRA	 observed	 during	 docking	 into	 RARα,	 RARB	 and	 RARγ,	 in	 order	 of	 their	 observation.	 (Right)	 Conformation	 clustering	
histograms	 summarising	 the	distribution	of	 the	conformations	of	9CRA	 that	were	observed	 in	docking	 to	RARα	 (blue),	RARβ	 (red)	and	RARγ	 (green).	53	potential	
docking	solutions	were	examined	in	RARα	(11	discarded	due	to	atypical	positioning),	78	potential	docking	solutions	were	examined	in	RARβ	(five	discarded	due	to	
atypical	positioning),	and	73	potential	docking	solutions	were	examined	in	RARγ	(none	discarded).		
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
ARTICLE	 Journal	Name	
6 	|	J.	Name.,	2012,	00,	1-3	 This	journal	is	©	The	Royal	Society	of	Chemistry	20xx	
Please	do	not	adjust	margins	
Please	do	not	adjust	margins	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	 3:	 (Left)	 The	 conformations	 of	 ATRA	 observed	 during	 docking	 into	 RARα,	 RARB	 and	 RARγ	 with	 respect	 to	 the	 alkene	 stereochemistry,	 in	 order	 of	 their	
observation.	(Right)	Conformation	clustering	histograms	summarising	the	distribution	of	the	conformations	of	ATRA	that	were	observed	in	docking	to	RARα	(blue),	
RARβ	(red)	and	RARγ	(green).	222	potential	docking	solutions	were	examined	in	RARα,	223	potential	docking	solutions	were	examined	in	RARβ,	and	185	potential	
docking	solutions	were	examined	 in	RARγ.None	of	 these	solutions	were	discarded	due	to	unrealistic	positioning.	The	conformation	 frequency	distribution	profiles	
differ	significantly	between	each	receptor	(Fisher’s	exact	test,	P<0.001).	
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Figure	4	Ligand	interaction	diagram	of	the	most	frequent	encountered	ATRA	conformation,	ATRA-Conformation	1,	in	the	RARγ	(PDB:	2LBD)	binding	pocket	(mesh),13	
highlighting	the	predominantly	hydrophobic	nature	of	the	binding	of	retinoids	to	RARα,	 -β	and	-γ.	A	cluster	of	polar	residues	(K236,	R278	and	S289	 in	the	case	of	
RARγ)	at	the	base	of	the	pocket	anchor	the	retinoid	via	the	carboxylate.	Helix	12	(H12,	in	yellow)	is	positioned	in	the	holo	conformation,	covering	the	opening	to	the	
pocket	(hydrogen	-atoms	were	omitted	for	clarity	in	this	and	all	other	figures).	
	 Figure	4	 shows	 the	 structural	 features	of	 the	RAR	binding	
pocket	(ATRA	conformation	1	in	RARγ	is	shown	as	an	example),	
and	 highlights	 the	 mildly	 twisted	 ligand	 conformation,	 the	
predominantly	 hydrophobic	 nature	 of	 the	 pocket,	 and	 the	
small	polar	cluster	at	the	end	that	associates	with	the	retinoid	
carboxylate.	The	gem-dimethyl	moiety	of	the	6-ring	(C21/C22)	is	
closely	 associated	with	 the	 rich	 hydrophobicity	 at	 the	 top	 of	
the	pocket,	and	the	two	alkenyl	methyl	groups	(C12	&	C16)	are	
well	 positioned	 for	 hydrophobic	 contacts	with	 the	 bottom	of	
the	 pocket.	 The	 opening	 of	 the	 pocket	 is	 enclosed	 by	 H12	
which	 traps	 the	 retinoid	 inside	 and	 interacts	 with	 the	
hydrophobic	region	of	the	retinoid.13,14,31	A	strong	hydrophobic	
interaction	 is	 required	 here	 to	 provide	 a	 stable	 platform	 for	
the	recruitment	of	coactivator	peptides	to	the	outer	surface	of	
H12.	 The	 carboxylate	 is	 shown	 near	 to	 the	 polar	 cluster	
allowing	strong	polar	 interactions	with	the	conserved	Arg	and	
Ser	and	Lys236	in	this	region.	The	slight	twist	in	overall	 ligand	
shape	first	observed	in	the	conformational	analysis	agrees	with	
the	shape	of	the	RARγ	binding	pocket,	and	accommodates	the	
sterically	demanding	gem-dimethyl	group	into	the	widest	part	
of	the	pocket.	
The	observed	conformational	distribution	of	ATRA	in	RARγ	
was	 particularly	 interesting	 when	 comparing	 the	 docking	
solutions	 of	 ATRA	 with	 that	 of	 the	 experimental	 crystal	
structure	 in	 the	 literature.13,29	Figure	5	shows	a	superposition	
of	 the	 highest	 scoring	 poses	 of	 the	 most	 sampled	
conformations	 in	RARγ	(conformations	1	&	7)	with	the	crystal	
structure	 (PDB:	 2LBD),	 highlighting	 a	 generally	 good	
agreement.	 The	 difference	 in	 6-ring	 positioning	 between	
conformation	 1	 &	 7	 is	 due	 to	 the	 differences	 in	 alkene	
conformation	between	the	C8-C9	double	bond	adjacent	to	the	
ring,	and	the	polyene	chain.	When	these	contrasting	positions	
are	 compared	 with	 the	 2LBD	 ligand	 position,	 the	 position	 in	
the	crystal	structure	can	essentially	be	described	as	an	average	
of	 the	 two	 binding	 poses.	 This	 is	 particularly	 relevant,	 since	
given	 the	 resolution	 of	 the	 crystal	 structure	 (2.06	Å)	 and	 the	
high	 conformational	 flexibility	 of	 the	 ligand,	 it	 would	 have	
undoubtedly	 been	 difficult	 to	 unequivocally	 resolve	 multiple	
conformations	of	ATRA.	This	example	therefore	highlights	the	
potential	 benefits	 of	 using	 a	 docking	 analysis	 such	 as	 that	
described	 here	 to	 understand	 the	 accessible	 ligand	
conformations	 in	 a	 binding	 site,	 and	 to	 use	 the	 resulting	
information	 to	 better	 understand	 the	 fitting	 of	 a	 ligand	 to	
electron	 density	 from	 X-ray	 diffraction,	 particularly	 when	
dealing	with	medium	resolution	diffraction	data.	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	5	Structural	overlay	of	the	binding	poses	of	ATRA	in	the	binding	pocket	of	
RARγ	 (mesh)	 calculated	 using	 X-ray	 diffraction	 (PDB:	 2LBD)	 and	 docking	
(conformation	 1	 and	 conformation	 7).	 The	 highest	 scoring	 examples	 of	
conformations	 1	 and	 7,	 respectively,	 show	 the	 same	 position	 of	 the	 polyene	
chain	to	that	in	the	crystal	structure.		
Therefore,	 given	 the	 conformational	 flexibility	 of	 ATRA,	 the	
range	 and	 frequency	 of	 the	 conformations	 selected	 during	
docking	highlighted	 in	 Figure	 3,	 and	 the	observation	 that	 the	
crystal	 structure	of	ATRA	 in	RARγ	could	 represent	an	average	
of	a	number	of	conformations,	we	can	suggest	that	ATRA	may	
well	bind	to	its	targets	in	a	variety	of	conformations,	and	that	
at	 physiological	 temperature,	 each	 conformation	 may	 be	
readily	 accessible	 and	 interconverted	 while	 bound	 in	 the	
pocket.29	
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Figure	 6	 Highest	 scoring	 docking	 pose	 of	 9CRA	 docked	 into	 the	 RARα	 binding	
pocket.	The	RARα-specific	residue	Ser232	is	highlighted,	demonstrating	the	close	
distance	between	the	ring	methyl	and	the	serine	side	chain.	
This	 analysis	 was	 further	 applied	 to	 the	 ATRA	 isomer,	 9CRA,	
which	 differs	 from	 ATRA	 by	 a	 change	 in	 geometry	 along	 the	
polyene	chain	due	to	the	different	alkene	configuration	at	C9.	
9CRA	exhibits	very	similar	positioning	in	RARα,	β	and	γ,	with	a	
clear	 preference	 for	 conformation	 1	 in	 all	 cases.	 Further	
examination	of	the	docking	poses	revealed	the	key	role	of	the	
RARα-specific	 residue	 Ser232	 in	 this	 strict	 discrimination	
against	 conformation	 2.40,41	 As	 shown	 in	 Figure	 6,	 the	 C7	
methyl	 group	 of	 the	 β-ionone	 ring	 of	 9CRA	 conformation	 1	
must	 point	 towards	 Ser232	 in	 order	 to	 accommodate	 the	
hydrophobic	region	in	the	pocket.	However,	due	to	the	ease	of	
rotation	about	the	C5-C8	single	bond,	this	methyl	rotates	away	
from	a	direct	clash	with	Ser232	and	towards	the	neighbouring	
Leu266	 and	 Leu269,	 thus	 allowing	 the	 formation	 of	 strong	
hydrophobic	 contacts.	 While	 the	 same	 rotation	 would	 also	
occur	 with	 conformation	 2,	 it	 is	 likely	 that	 one	 of	 the	
corresponding	methyls	of	the	gem-dimethyl	moiety	would	still	
point	 directly	 at	 Ser232,	 causing	 an	 unfavourable	 clash	 that	
explains	 why	 the	 docking	 algorithm	 exclusively	 selected	
conformation	1	as	most	favourable	in	RARα.18	
The	 corresponding	 residues	 in	 RARβ	 (Ala225)	 and	 RARγ	
(Ala234)	on	the	other	hand	allow	closer	proximity	to	the	single	
or	 gem-dimethyl	 groups,	 which	 explains	 why	 the	 docking	
algorithm	 is	 able	 to	 allow	 conformation	2	 in	RARβ	and	RARγ.	
Nevertheless,	the	much	greater	steric	size	of	the	gem-dimethyl	
group	is	 likely	to	cause	a	degree	of	steric	clashing	in	this	tight	
area	 of	 the	 pocket,	 and	 conformation	 1	 is	 therefore	 still	 the	
favoured	conformation.19	
	
	
	
	
	
	
	
	
	
	
	
Figure	 7	 Highest	 scoring	 docking	 poses	 of	 9CRA	 and	 ATRA	 overlaid	 with	 the	
binding	 pose	 of	 9CRA	 in	 the	 RARγ	 binding	 pocket	 as	 determined	 by	 X-ray	
diffraction	 (PDB:	3LBD).42	The	 same	9CRA	conformation	 (9CRA	conformation	1)	
was	selected	by	docking	as	in	the	crystal	structure,	with	similar	positioning.	
When	 the	highest	 scoring	docking	pose	of	 9CRA	 in	RARγ	was	
compared	 to	 that	of	 the	crystal	 structure	of	9CRA	 in	 the	PDB	
(PDB:	 3LBD),	 good	 agreement	was	 observed	 (Figure	 7).42	 The	
docked	 structure	 is	 positioned	 more	 towards	 the	 top	 of	 the	
pocket,	but	the	two	structures	both	adopt	conformation	1	and	
the	 overall	 positioning	 is	 very	 similar,	 thus	 providing	 further	
confidence	 in	the	docking	protocol	 (the	binding	pose	of	9CRA	
in	 RARβ	 as	 calculated	 by	 docking	 was	 also	 compared	 to	 the	
literature	crystal	structure	PDB:	1XDK,15	showing	equally	good	
agreement,	 see	 ESI).	 When	 the	 highest	 scoring	 solution	 of	
ATRA	 in	 RARγ	 was	 superimposed,	 the	 two	 poses	 were	 very	
similar,	 with	 the	 exception	 that	 the	 β-ionone	 ring	 adopted	
opposite	orientations,	 and	 the	methyl	 at	 the	 carboxylate	end	
was	 found	 to	 be	 pointed	 downwards,	 rather	 than	 upwards.	
Furthermore,	 when	 the	 positions	 of	 the	 carboxylate	 moiety	
between	 the	 9CRA	 binding	 poses	 and	 that	 of	 ATRA	
conformation	 1	 were	 compared,	 clear	 differences	 were	
observed,	 dictated	 by	 their	 different	 chemical	 structures.	
Where	 ATRA	 is	 well	 placed	 for	 short,	 strong	 polar	 contacts	
between	 both	 oxygens	 of	 the	 carboxylate	 with	 Arg278	 and	
Ser289,	 only	 the	 lower	 oxygen	 is	 available	 for	 hydrogen	
bonding	 to	 these	 residues	 in	 9CRA.	 Similar	 effects	 were	
observed	in	RARα	and	β.	Based	on	these	observations,	one	can	
predict	that	ATRA	is	more	suited	than	9CRA	for	binding	to	the	
RARs,	and	indeed	has	been	demonstrated	experimentally	(vide	
infra).24,26	 It	 therefore	 follows	 that	 based	 on	 this	 docking	
analysis,	good	synthetic	mimics	of	ATRA	should	possess	a	more	
linear	 shape,	 which	 will	 result	 in	 the	 positioning	 of	 the	
carboxylate	 group	 closer	 to	 the	 polar	 cluster	 to	 enable	
effective	binding	interactions	to	the	RARs.	
With	this	knowledge	in	hand,	we	then	analysed	the	docking	
solutions	 of	 ATRA-analogue	 EC23	 with	 reference	 to	 the	 top	
clustering	 solution	 of	 ATRA	 in	 RARγ.	 Figure	 8	 shows	 a	
superposition	 of	 the	 highest	 scoring	 examples	 of	 ATRA	
conformation	1,	ATRA	conformation	7	and	EC23,	and	highlights	
the	 similarity	 in	 the	 predicted	 overall	 positioning	 of	 these	
binding	poses,	with	each	exhibiting	an	extended,	linear	shape.	
The	carboxylate	of	EC23	lies	 in	an	identical	position	to	that	of	
ATRA,	 allowing	 stabilising	 interactions	 to	 the	 polar	 cluster	 at	
the	 end	 of	 the	 pocket.	 Interestingly,	 the	
tetrahydronaphthalene	hydrophobic	region	of	EC23	essentially	
occupies	 both	 possible	 positions	 of	 the	 6-membered	 ring	 of	
ATRA	 according	 to	 ATRA	 conformation	 1	 and	 ATRA	
conformation	 7.	 By	 straddling	 both	 positions,	 interactions	
between	the	hydrophobic	 region	of	EC23	and	both	the	upper	
(Leu271	&	Ala234)	and	lower	(Phe230)	parts	of	the	pocket	are	
improved,	and	the	two	gem-dimethyl	groups	extend	the	reach	
of	the	ligand	into	all	corners	of	the	highly	hydrophobic	opening	
of	 the	 pocket.13,42	 The	 central	 acetylene	 linker	 is	 positioned	
slightly	 nearer	 the	 top	 of	 the	 pocket	 than	 ATRA,	 enhancing	
interactions	with	Ala234,	but	reducing	the	strength	of	contacts	
with	Met272	and	 Ile275.39	 In	 comparison	 to	ATRA,	 the	 larger	
benzoate	polar	region	allows	a	closer	positioning	to	the	top	of	
the	 pocket	 (Leu233),	 near	 the	 polar	 cluster,	 though	 slightly	
further	from	the	bottom	(Arg274	&	Ile275).				
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Figure	 8:	 Structural	 overlay	 of	 the	 highest	 scoring	 docking	 poses	 of	 the	 most	
frequent	binding	conformations	of	ATRA,	and	EC23	in	the	binding	pocket	of	RARγ	
(PDB:	2LBD)	 (mesh)	calculated	by	docking	simulation.	The	cyclohexenyl	 rings	of	
ATRA	 conformation	 1	 and	ATRA	 conformation	 7	 are	 in	 positions	 that	 are	 both	
straddled	by	the	tetrahydronaphthalene	hydrophobic	region	of	EC23.	
In	 general,	 according	 to	 the	 docking	 results,	 EC23	 fills	 the	
binding	pockets	of	RARα,	β	and	γ	more	completely	than	ATRA,	
particularly	 in	 the	 hydrophobic	 areas	 at	 the	 opening	 of	 the	
pocket	near	H12	and	next	 to	 the	polar	cluster	at	 its	end.	The	
hydrophobic	region	of	EC23	also	occupies	the	majority	of	both	
hydrophobic	region	positions	of	ATRA	conformations	1	and	7.	
Given	 that	 EC23	 occupies	 the	 same	 positioning	 as	 ATRA,	 but	
interacts	with	more	of	 the	binding	pocket,	 one	would	expect	
EC23	to	exhibit	equal,	or	greater,	binding	affinity	for	the	RARs	
when	compared	to	ATRA.	
When	the	docking	results	of	the	meta-oriented	carboxylate	
retinoid	 EC19	 were	 compared	 to	 those	 of	 EC23,	 clear	
differences	 in	 binding	 poses	 were	 identified.	 The	 meta-
carboxylate	 of	 EC19	 was	 positioned	 toward	 the	 top	 of	 the	
pocket	(Figure	9,	in	the	case	of	RARγ).	Ostensibly,	this	is	not	an	
unfavourable	positioning,	but	 it	 is	one	 that	moves	one	of	 the	
carboxylate	 oxygens	 further	 from	 one	 of	 the	 polar	 cluster	
residues	(Arg278)	and	EC19	will	 likely	form	fewer	and	weaker	
interactions	 with	 this	 residue	 than	 those	 of	 EC23.13	 This	
alternative	positioning	of	 the	 carboxylate	 can	also	be	 seen	 in	
the	 binding	 poses	 in	 RARα	 and	 RARβ,	 where	 the	 increased	
distance	(and	poor	angle)	to	the	corresponding	serine	residue	
(O--H	 distance:	 4.1,	 3.9	 and	 3.5	 Å,	 in	 RARα,	 β	 and	 γ,	
respectively)	 likely	 eliminates	 any	 hydrogen	 bonding	
interaction.	 Furthermore,	 in	 comparison	 to	 EC23,	 the	 highest	
scoring	binding	poses	of	EC19	do	not	form	additional	hydrogen	
bonds	 to	 the	 amide	 NH	 of	 Phe286-Ser287	 in	 RARα	 and	
Phe279-Ser280	 in	 RARβ,	 though	 the	 positioning	 of	 the	
carboxylate	of	EC19	is	 likely	reasonable	for	hydrogen	bonding	
to	this	amide	in	RARγ.	These	strong	interactions	are	thought	to	
anchor	 retinoids	 inside	 the	 binding	 pockets	 of	 the	 RARs	 and	
their	 absence	 or	 reduced	 strength	 in	 the	 case	 of	 EC19	 may	
result	in	a	reduced	binding	affinity.13	
	
	
Figure	 9:	 Structural	 overlay	 of	 the	 highest	 scoring	 docking	 poses	 of	 EC23	 and	
EC19	 in	 the	binding	pocket	of	RARγ	 (PDB:	2LBD)	 (mesh)	 calculated	by	docking.	
EC19	exhibits	an	opposite	position	of	the	hydrophobic	region	due	to	the	need	to	
accommodate	the	meta-carboxylate.	
The	 other	 notable	 feature	 of	 the	 comparison	 between	 EC19	
and	 EC23	 are	 the	 differences	 in	 the	 positions	 of	 their	
hydrophobic	 regions.	 In	 RARγ	 (Figure	 9)	 the	 hydrophobic	
regions	of	the	two	retinoids	are	clearly	shown	in	two	opposing	
orientations.	 While	 this	 effectively	 fills	 the	 same	 part	 of	 the	
pocket,	 the	 upper	 gem-dimethyl	 of	 EC19	 is	 positioned	 more	
towards	Ala234	at	the	top,	while	that	of	EC23	is	pointed	more	
towards	 to	 the	 opening	 of	 the	 pocket	 (Ile412).	 This	 EC19	
positioning	 is	 likely	 to	 reduce	 the	 hydrophobic	 interactions	
with	the	 lower	 left	part	of	the	pocket.	 In	RARα,	EC19	exhibits	
the	same	hydrophobic	region	orientation	as	EC23,	but	as	with	
RARγ	 the	 overall	 positioning	 is	 biased	more	 towards	 the	 top	
part	 of	 the	 pocket,	 thus	 likely	 reducing	 the	 strength	 of	
interaction	with	the	bottom	of	the	binding	pocket.	
However,	as	 shown	 in	Figure	10,	EC23	and	EC19	exhibit	a	
much	more	marked	difference	in	positioning	in	RARβ.	In	order	
to	 accommodate	 the	 meta-carboxylate	 group,	 the	
hydrophobic	 region	of	 EC19	 is	 oriented	upwards	 towards	 the	
RARβ-specific	cavity	at	 the	 top	of	 the	pocket,	 rather	 than	 the	
typical	 retinoid	 positioning	 exemplified	 by	 EC23.	 This	
maximises	 hydrophobic	 contacts	 in	 this	 upper	 region,	 and	
EC19	 is	 closely	 positioned	 for	 hydrophobic	 interactions	 with	
Leu262,	 Ile263	 and	 Ile380,	 among	 other	 residues.	 A	 widely	
employed	 design	 strategy	 for	 the	 development	 of	 RARβ-
specific	 retinoids	 involves	 the	 addition	 of	 sterically	 bulky	
lipophilic	 groups	 that	 would	 be	 positioned	 towards	 this	
hydrophobic	 cavity.	 Therefore,	 given	 the	 orientation	 of	 EC19	
towards	 this	 cavity,	 as	 predicted	 by	 docking,	 one	 can	 predict	
that	the	molecule	exhibits	specificity	towards	RARβ.20,43	
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Figure	10:	 Structural	 overlay	of	 the	highest	 scoring	docking	poses	of	 EC23	and	
EC19	 in	 the	 binding	 pocket	 of	 RARβ	 (PDB:	 1XAP)	 (mesh)	 calculated	by	 docking	
simulation.	The	EC19	hydrophobic	 region	 is	clearly	oriented	towards	 the	RARβ-
specific	cleft	at	the	top	of	the	pocket	
In	 the	next	step,	 the	corresponding	methyl	esters	of	EC19	
and	EC23	were	docked	in	order	to	confirm	the	key	role	of	the	
carboxylate	interaction	with	the	polar	cluster	at	the	bottom	of	
the	binding	pockets	of	the	RARs.9	 In	principal,	with	a	reduced	
ability	to	form	a	hydrogen	bond,	one	would	expect	that	these	
esters	 (EC23Me,	 and	 EC19Me)	 exhibit	 reduced	 binding	
affinities.	 Stem-cell	 differentiation	 experiments	 involving	
EC23Me	and	EC19Me	 in	our	 laboratories	 indicate	significantly	
reduced	activity	in	vitro,44	though	the	level	of	activity	may	well	
be	 determined	 by	 the	 ease,	 and	 rate	 of	 hydrolysis	 to	 the	
corresponding	 acid	 and	 therefore,	 the	 time	 course	 of	 the	
experiment.45	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	11:	Comparison	between	the	highest	scoring	docking	poses	of	EC23	and	
EC23Me	in	RARγ	(PDB:	2LBD)	(mesh).	Docking	predicts	the	same	positioning	for	
the	two	ligands,	but	with	EC23Me	moved	back	slightly	towards	the	entrance	to	
the	pocket	in	order	to	accommodate	the	methyl	ester	group.	
Figure	 11	 shows	 a	 comparison	 of	 the	 docking	 poses	 of	 EC23	
and	 EC23Me	 in	 RARγ,	 and	 highlights	 the	 effect	 of	 the	 ester	
group.	In	order	to	accommodate	the	ester	methyl	group	in	this	
tight,	and	relatively	hydrophilic	part	of	the	pocket	EC23Me	has	
been	 pushed	 backwards	 towards	 the	 mouth	 of	 the	 pocket.	
While	 the	 carbonyl	 oxygen	 is	 still	 well	 placed	 for	 hydrogen	
bonding	interactions	with	Ser289,	this	movement	results	in	the	
ester	oxygen	being	 relatively	 far	 from	Arg278	 (2.7	Å)	 is	more	
significant.	 These	 movements	 both	 serve	 to	 reduce	 the	
efficacy	of	polar	contacts	with	 the	polar	cluster	at	 the	end	of	
the	 pocket	 and	 illicit	 short	 clashes	 with	 the	 polar	 cluster	
residues	 disrupting	 any	opportunity	 for	methyl	 ester	 oxygens	
to	 form	 hydrogen	 bond	 interactions.	 Similar	 effects	 are	 seen	
when	 comparing	 EC23	 and	 EC23Me	 in	 both	 RARα	 and	 β,	
though	 in	 the	 case	 of	 RARβ	 in	 particular,	 the	 change	 in	
positioning	is	(particularly	the	conserved	arginine).13	Given	the	
reduction	in	the	number,	and	strength	of	the	polar	contacts	in	
this	 area,	 one	 would	 expect	 that	 the	 binding	 affinity	 of	
EC23Me	in	the	RARs	would	be	reduced	in	comparison	to	EC23.		
	
	
	
	
	
	
	
	
	
	
	
	
Figure	12:	Comparison	of	the	highest	scoring	docking	poses	of	EC19	and	EC19Me	
in	RARα	(PBD:	3KMR)	(mesh).	The	ester	of	EC19Me	is	forced	into	an	alternative	
positioning,	which	 sacrifices	hydrogen	bonds	with	 the	polar	 cluster	 side	 chains	
but	significantly	enhances	a	polar	contact	with	the	main	chain	amide.	EC19Me	is	
positioned	closer	to	the	hydrophobic	roof	of	the	pocket.	
When	 comparing	 the	 docking	 poses	 of	 EC19	 and	 EC19Me	
(Figure	 12)	 an	 analogous	 orientation	 of	 the	 ester	 away	 from	
the	 polar	 cluster	 was	 observed	 in	 RARβ	 and	 γ,	 but	 a	 more	
significant	 disparity	 in	 binding	 pose	 was	 noticed	 in	 RARα.	
Where	EC19	lacks	hydrogen	bonding	with	the	polar	cluster	and	
one	of	the	carboxylate	oxygens,	EC19Me	in	RARα	is	unable	to	
form	hydrogen	bonds	with	 the	Arg276	or	 Ser287	 side-chains.	
However,	 to	 compensate,	 the	 carbonyl	 oxygen	 is	 positioned	
close	to	the	Phe286-Ser287	amide	link,	and	forms	a	significant	
(O--H	 distance:	 1.65	 Å)	 hydrogen	 bond	 interaction	 with	 the	
amide	NH.	As	a	result	of	this	atypical	positioning,	the	benzoate	
polar	 regions	of	 the	 two	exhibit	opposing	orientations,	which	
in	 turn	 forces	 the	 hydrophobic	 region	 of	 EC19Me	 further	
towards	the	top	part	of	the	pocket.	In	comparison	to	EC19,	the	
EC19Me	 hydrophobic	 region	 fills	 the	 RARα	 pocket	 more	
completely.	 These	 observations	 suggest	 that	 EC19Me	 could	
exhibit	 stronger	 binding	 to	 RARα	 than	 EC19	 through	 an	
atypical	binding	pose.	
The	 hydrogen	 bonding	 characteristics	 of	 each	 retinoid	 in	
RARα	are	compared	in	Figure	13	(Comparisons	for	RARβ/γ	are	
shown	 in	 the	 ESI).	 Both	 ATRA	 and	 EC23	 form	 electrostatic	
contacts	 involving	 both	 carboxylate	 oxygens	 and	 the	
conserved	Arg	and	Ser	side	chains,	and	with	the	amide	NH	of	
the	 serine	 in	 RARα,	 β	 and	 γ.	 In	 contrast,	 due	 to	 the	 altered	
geometry	 of	 the	 ligand,	 9CRA	 is	 only	 able	 to	 form	 hydrogen	
bonding	interactions	with	one	of	 its	carboxylate	oxygens.	This	
situation	is	mirrored	with	EC19,	where	the	meta-carboxylate	is	
positioned	such	that	one	oxygen	 is	 far	 from	the	polar	cluster.	
With	the	methyl	esters,	steric	clashing	from	the	methyl	group	
and	slight	movement	away	from	the	polar	cluster	are	likely	to	
reduce	the	strength	of	hydrogen	bonding	interactions.		
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Figure	13:	Hydrogen	bonding	 characteristics	 of	 each	 retinoid	 in	RARα	 (PDB:	 3KMR)	 (mesh)	 according	 to	 the	docking	 study.	 The	majority	 of	 the	binding	pocket	 is	
represented	 in	mesh	 form,	 the	polar	 cluster	 residues	are	 shown	 in	a	 stick	 representation	without	unipolar	hydrogen	atoms,	and	 the	 ligands	are	 shown	 in	a	 stick	
representation	without	hydrogen	atoms.	Both	ATRA	and	EC23	are	well	placed	 for	polar	 contacts	via	both	carboxylate	oxygens.	Due	 to	 their	positioning,	only	one	
oxygen	of	the	carboxylates	of	EC19	and	9CRA	are	available	for	polar	interactions.	The	esters	EC23Me	and	EC19Me	are	positioned	further	from	the	polar	cluster	at	the	
bottom	pocket,	and	in	the	ester	group	of	EC19Me	is	pushed	towards	the	side	of	the	pocket,	enabling	a	short	hydrogen	bond	interaction	with	the	main	chain	Phe286-
Ser287	amide	group.	
MedChemComm	 	
ARTICLE	
This	journal	is	©	The	Royal	Society	of	Chemistry	20xx	 J.	Name.,	2013,	00,	1-3	|	12 		
Please	do	not	adjust	margins	
Please	do	not	adjust	margins	
With	the	observations	from	docking	in	hand,	it	was	possible	to	
assess	likely	binding	activity	by	analysing	the	overall	fit	of	each	
compound	to	RAR	LDBs	with	reference	to	structural	data	in	the	
literature	 (Table	 1).13,20,42	 This	 was	 then	 used	 to	 assign	 a	
predicted	 ranking	 for	 each	 retinoid	 that	 could	 be	 tested	
experimentally.	
	
Table	1:	Qualitative	assessment	of	the	docking	calculations.a	
Retinoid	 RAR	 	 Flexibility		 Hydrophobic	 	 Polar	 	 Fit	 	 Rank	
ATRA	 α	 	 High	 	 Top/Bottom	 	 Strong	 	 Good	 	 2	
	 	 β	 	 Highest	 	 Bottom	 	 	 Strong	 	 Good	 	 2	
	 	 γ	 	 High	 	 Top		 	 	 Strong	 	 Good	 	 2	
	
9CRA	 α	 	 Medium		 Top		 	 	 Medium		 Medium		 3	
	 	 β	 	 Medium		 Bottom	 	 	 Medium		 Medium		 4	
	 	 γ	 	 Medium		 Top		 	 	 Medium		 Good	 	 3	
	
EC23	 α	 	 Low		 	 Top/Bottom	 	 Strong	 	 Good	 	 1	
	 	 β	 	 Low		 	 Bottom	 	 	 Strong	 	 Good	 	 1	
	 	 γ	 	 Low		 	 Top/Bottom	 	 Strong	 	 Good	 	 1	
	
EC19	 α	 	 Low		 	 Bottom	 	 	 Medium		 Poor	 	 6	
	 	 β	 	 Low		 	 Top		 	 	 Medium		 Good	 	 3	
	 	 γ	 	 Low		 	 Top		 	 	 Medium		 Medium		 4	
	
EC23Me	α	 	 Low		 	 Top/Bottom	 	 Weak	 	 Good	 	 4	
	 	 β	 	 Low		 	 Top		 	 	 Weak	 	 Medium		 5	
	 	 γ	 	 Low		 	 Top/Bottom	 	 Weak	 	 Medium		 5	
	
EC19Me	α	 	 Low		 	 Top/Bottom	 	 Strong	 	 Medium		 5	
	 	 β	 	 Low		 	 Top		 	 	 Weak	 	 Medium		 6	
	 	 γ	 	 Low		 	 Top/Bottom	 	 Weak	 	 Medium		 6	
aA	ranking	for	each	retinoid	was	determined	based	upon:	1)	the	observed	
flexibility	within	the	binding	pocket	(number	of	binding	conformations);	2)	
whether	the	retinoid	interacts	with	the	top,	bottom	or	both	areas	of	the	
pocket	around	H12;	3)	the	perceived	strength	of	polar	contacts	based	on	the	
number	and	distance	to	the	polar	cluster;	and	4)	the	overall	fit.	
The	 rank	 ordering	 in	 Table	 1	 suggests	 that	 EC23	 is	 the	 best	
ligand	for	 interacting	strongly	with	al	three	RARs,	 followed	by	
ATRA	and	9CRA,	and	then	some	way	behind	is	EC19,	and	finally	
the	two	methyl	esters,	EC23Me	and	EC19Me:		
	
EC23	 >	ATRA	>	 [9CRAα,γ,	 EC19β]	 >	 [9CRAβ,	 EC19γ,	 EC23meα]	 >	
[EC23meβ,γ,	EC19meα]		>	[EC19α,EC19meβ,γ]	
	
Because	 hydrophobic	 ligand-protein	 interactions	 at	 the	 LBD	
entrance	may	be	important	determinants	of	biological	activity	
in	addition	to	ligand-LBD	affinity,	we	tested	the	rank	order	
	predictions	 using	 a	 binding	 assay	which	 reflected	 these	 dual	
functions	of	retinoid-RAR	interaction.			
	
Receptor	binding	assays	
The	 readout	 from	 the	 receptor	 binding	 assays	 was	 the	 FRET	
signal	 resulting	 from	 the	 association	 of	 a	 labelled	 coactivator	
protein	 with	 ligand-bound	 receptor	 LBD,	 and	 thus	 was	
dependent	 on	 two	 parameters:	 the	 affinity	 of	 ligand	 for	 the	
LBD	and	the	affinity	of	ligand-LBD	complex	for	the	coactivator,	
both	of	which	may	be	affected	by	the	binding	of	ligand	to	LBD.	
The	 binding	 curves	 (Figures	 14a-c)	 were	 interpreted	 by	
reference	 to	 the	 results	 of	 computational	 simulations	 of	 the	
effects	 of	 varying	 ligand/LBD	 and	 ligand-LBD/co-activator	
affinity	 (Figure	 14d).	 	 This	 computational	model	 showed	 that	
(1)	 differences	 in	 the	 level	 of	 the	 upper	 asymptote	 of	 the	
binding	curves	reflected	differences	in	co-activator	affinity	for	
the	 ligand-LBD	 complex;	 (2)	 variation	 in	 affinity	 of	 ligand	 for	
the	 LBD	 which	 did	 not	 affect	 ligand-LBD	 coactivator	 affinity	
results	 in	 a	 shift	 in	 the	midpoint	 (EC50)	of	 the	binding	 curve;	
and	(3)	changes	in	the	level	of	the	upper	asymptote	may	result	
from	changes	in	coactivator	affinity	for	the	ligand-LBD	complex	
alone,	or	changes	in	both	parameters.			
	 According	 to	 the	 experimental	 binding	 curves	 in	 Figure	
14a-c,	 all	 compounds	 except	 EC19	 showed	 strong	 binding	 to	
RARα	with	EC50	values	<	50	nM.	Overall,	the	EC50	values	agreed	
with	the	predicted	ranking,	except	for	the	methyl	esters	where	
EC23Me	was	 better	 than	 expected	 for	 RARβ	 and	worse	 than	
expected	for	RARγ,	and	EC19Me	was	better	than	expected	for	
RARβ	and	RARγ.	EC23	had	the	strongest	binding	affinity	(EC50	=	
3.7	nM)	compared	to	all	other	ligands.	Upper	asymptotes	were	
highest	for	ATRA	and	EC23	compared	to	EC19	and	9CRA,	with	
data	 for	9CRA	 in	particular	suggesting	a	relatively	poor	ability	
to	 induce	 co-activator	 recruitment.	 	 RARβ	 displayed	 a	
narrower	 range	 of	 ligand	 binding	 affinities,	with	 EC23	 having	
the	greatest	affinity	(EC50	=	3.3	nM)	and	9CRA	the	lowest	(EC50	
=	 27.5	 nM).	 In	 contrast	 to	 RARα,	 the	 upper	 asymptotes	
suggested	 that	 co-activator	 recruitment	 through	 RARβ	 was	
optimal	for	ATRA,	but	relatively	inefficient	for	EC23	and	9CRA.	
Furthermore,	 EC19	 had	 a	 comparably	 high	 affinity	 for	 RARβ,	
and	 ligand	 binding	 also	 facilitated	 efficient	 co-activator	
recruitment.	 For	 RARγ,	 ATRA	 and	 EC23	 had	 similarly	 high	
binding	 affinities	 (EC50	 =	 14.7	 nM	 and	 16.8	 nM,	 respectively)	
while	 EC19	 the	 lowest	 (EC50	 =	 96.4	 nM)	 and	 an	 intermediate	
value	 for	 9CRA.	 Conversely,	 9CRA	had	 the	 highest	 asymptote	
suggesting	 a	 greater	 efficiency	 of	 co-activator	 recruitment	
through	RARγ	compared	to	the	other	ligands,	with	EC19	being	
the	 least	 effective.	 The	 binding	 affinities	 for	 the	 endogenous	
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retinoids	 were	 similar	 with	 respect	 to	 rank	 order	 to	 those	
reported	elsewhere.24,46	
	
	
Figure	14:	Three-parameter	sigmoid	curves	fitted	to	binding-assay	data	for	ATRA	(!),	9-
CRA	("),	EC23	(!)	and	EC19	(")	with	RARα	(a;	blue	lines),	-β	(b;	red	lines)	and	–γ	(c;	
green	lines).	Ordinate	axes	are	FRET	ratio	values	normalised	to	the	lower	asymptote	for	
each	curve.	Binding-assay	simulations	are	shown	in	(d).	The	binding	assay	results	show	
that	the	EC50	of	EC23	for	RARα	was	lower	than	ATRA,	9-CRA	and	EC19.	For	RAR-β,	the	
EC50	of	EC23	was	slightly	lower	than	ATRA,	9-CRA	and	EC19.	With	RAR-γ,	the	EC50	of	
EC23	 was	 similar	 to	 ATRA,	 but	 9-CRA	 and	 EC19	 had	 a	 lower	 binding	 affinity.	 	 EC50	
values	estimated	from	these	binding	curves	are	given	 in	Table	3.	 In	the	binding	assay	
simulations	with	COPASI	 (d),	 the	red	 line	represents	ATRA	as	 the	basal	condition,	 the	
blue	 line	models	an	 increased	affinity	of	 co-activator	 for	 the	 ligand-LBD	complex,	 the	
green	 line	 models	 an	 increased	 affinity	 of	 ligand	 for	 LBD	 and	 also	 co-activator	 for	
ligand-LDB,	the	black	line	represents	an	increase	in	affinity	of	ligand	for	the	LBD	alone,	
and	dashed	lines	represent	higher	ligand-LBD	affinity	with	progressively	lower	affinities	
of	co-activator	for	ligand-LBD	(see	SI	for	details).	In	(d),	the	ordinate	units	are	arbitrary.	
	
	
Table	2:	Estimated	EC50	values	(95%	confidence	ranges	in	parentheses)	for	
ATRA,	9CRA,	EC23,	EC23Me,	EC19	and	EC19Me	with	RAR-α,	-β	and	-γ.a	n	=	3).	
Retinoid	 RARα	EC50
a
	(nM)	 	 RARβ	EC50
a	(nM)		 	 RARγ	EC50
a	(nM)	
ATRA	 16.0	(8.8	-	29.4)	 	 17.6	(15.2	-	20.3)		 14.7	(5.4	-	39.8)	
9CRA	 28.8	(0.2	-	5343.4)	 27.5	(15	-	50.4)	 	 36.7	(12.8	-	105.6)	
EC23	 3.7	(1.4	-	9.5)	 	 3.3			(1.1	-	8.4)	 	 16.8	(1.7	-	163.6)	
EC19	 194.0	(57.6	–	653)	 12.1	(8	-	18.3)	 	 96.4	(22.7	-	409.5)	
EC23Me	20.5	(11.8	-	35.4)		 14.0	(8.8	-	22.5)	 	 847.6	(182.3	-	3940.8)	
EC19Me	49.4	(7.5	-	327.2)			 30.1	(18.1	–	50)	 	 97.7	(36.1	-	264.3)	
	
The	 similarity	 in	 EC50	 values	 obtained	 for	 ATRA	 and	 EC23,	
suggest	 that	 EC23	 is	 an	 excellent	 ATRA	 mimic	 (vide	 supra).	
EC23	clearly	also	exhibits	 stronger	binding	 to	RARα/β	 than	 to	
RARγ.	 The	 docking	 analysis	 indicated	 that	 the	 hydrophobic	
region	of	EC23	 fills	 the	slightly-wider	RARα/β	binding	pockets	
more	 completely	 than	 ATRA,	 and	 this	 is	 supported	 by	 the	
binding	assay	data	indicating	higher	binding	affinity.	However,	
while	EC23	is	likely	a	good	ligand	for	the	RARs,	it	may	be	a	poor	
transcriptional	regulator	via	RARβ	as	a	result	of	a	reduction	in	
ability	to	recruit	coactivator.	Given	that	the	stem	cell-induction	
activity	of	EC23	 is	higher	than	that	of	ATRA,9	this	 implies	that	
this	 biological	 activity	 might	 be	 driven	 more	 through	
interaction	of	EC23	with	RARα.		
	 The	 lower	 binding	 affinity	 of	 9CRA	 compared	 to	 ATRA	
would	 be	 predicted	 from	 the	 docking	 studies	 due	 to	 the	
different	 geometry	 and	 concomitant	 reduction	 in	 sites	
available	 for	 polar	 contacts,	 and	 is	 consistent	 with	 other	
reports.24	 Secondly,	 EC19	 exhibits	 selectivity	 in	 binding	 to	
RARβ	over	RARα/γ,	a	 result	 supported	by	 the	docking	studies	
where	 the	 positioning	 of	 the	 hydrophobic	 region	 of	 EC19	
provided	a	better	fit	to	the	RARβ-specific	cleft	at	the	top	of	the	
pocket.47	 Given	 this	 selectivity	 for	 RARβ,	 EC19	 represents	 an	
excellent	starting	point	for	further	structural	optimisation.	Few	
examples	 of	 RARβ-selective	 retinoids	 containing	 this	 meta-
carboxylate	 motif	 exist	 in	 the	 literature,3,26	 and	 given	
confirmed	 links	 between	 RARβ	 and	 the	 treatment	 of	 cancers	
(among	 other	 conditions),4,48–50	 such	 a	 scaffold	 would	 be	
interesting	 to	 explore,	 particularly	 since	 the	 synthetic	
methodology	 associated	 with	 similar	 compounds	 is	 well	
understood.9,21,51	
Finally,	 as	 might	 be	 expected,	 the	 methyl	 ester	 of	 EC23	
exhibited	 reduced	 binding	 affinity	 compared	 to	 the	 parent	
compound,	 particularly	 for	 RARγ	 (Table	 3).	 This	 is	 fully	
consistent	 with	 the	 docking	 simulation,	 where	 a	 movement	
away	from	the	polar	cluster	and	likely	steric	clashing	with	the	
methyl	 group	 would	 reduce	 electrostatic	 contacts.	 However,	
only	 EC23Me	 in	 RARγ	 exhibited	 a	 large	 decrease	 in	 binding	
affinity,	 and	 it	 may	 be	 that	 the	 hydrophobic	 interactions	
between	 the	 esters	 and	 the	 other	 hydrophobic	 end	 of	 the	
pocket	 are	 of	 a	 comparable	 strength	 to	 the	 corresponding	
acids	 in	 RARα/β.	 This	 was	 indicated	 in	 the	 docking	 studies,	
where	 only	 minor	 movements	 were	 predicted	 in	 the	
hydrophobic	 region	 positioning	 of	 the	 esters	 (with	 the	
exception	 of	 EC23Me	 in	 RARβ).	 The	 presence	 of	 the	 methyl	
ester	in	EC19Me	reduced	the	binding	affinity	for	RARβ	(but	not	
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RARγ),	which	may	 result	 from	movement	of	 the	hydrophobic	
region	and	 reduction	 in	hydrogen	bonding	efficacy.	However,	
as	 predicted	 from	 the	 short	 hydrogen	 bond	 formed	between	
the	EC19Me	carbonyl	oxygen	and	the	conserved	serine	amide	
NH,	EC19Me	exhibited	a	significant	increase	in	binding	affinity	
for	 RARα	 compared	 to	 EC19.	 The	 esters	 generally	 exhibited	
reduced	 activity	 in	 cellular	 differentiation	 assays,44	 and	 the	
reduction	 in	 the	 binding	 affinities	 of	 these	 compounds	
compared	 to	 the	 corresponding	 acids	 is	 therefore	 a	 good	
rationale	for	this	observation.		
Conclusions	
In	 this	 study,	 receptor	 binding	 assays	 and	 detailed	molecular	
modelling	 have	 been	 combined	 to	 investigate	 the	 molecular	
basis	 of	 the	 biological	 activity	 of	 synthetic	 retinoids	 in	
comparison	with	 the	 natural	 ligands.	 As	 shown	previously,	 in	
cell	 differentiation	 assays,	 EC23	 was	 more	 potent	 even	 at	
lower	concentrations	compared	to	the	natural	 ligand	ATRA	at	
causing	 neural	 differentiation.	 In	 contrast,	 EC19	 caused	 the	
development	 of	 epithelial-like	 structures,	 especially	 in	 the	
TERA2.cl.SP12	 stem	 cell	 line.52	 These	 differences	 can	 be	
rationalised	 by	 the	 relative	 binding	 affinities	 to	 the	 three	
protein	 targets	 examined	 in	 this	 study,	 i.e.	 EC23	 exhibited	
higher	 binding	 affinities	 for	 RARα,	 RARβ	 and	 RARγ	 than	 both	
ATRA	 and	 9CRA.	 Conversely,	 EC19	 had	 considerably	 lower	
binding	affinities	 for	both	RARα	and	RARγ	compared	to	EC23,	
but	higher	binding	affinity	for	RARβ.	These	results	may	explain	
why	 EC23	 can	 successfully	 induce	 stem	 cell	 differentiation	
resulting	in	functional	neural	cells	in	a	similar	manner	to	ATRA,	
but	at	 lower	concentrations.	However,	since	EC19	bound	only	
RARβ	efficiently,	this	suggests	that	neurogenesis	in	response	to	
EC23	 may	 be	 driven	 more	 via	 a	 combination	 of	 all	 the	 RAR	
receptors.	 Interestingly,	 stem	 cell	 differentiation	 induced	 by	
EC19	 gives	 an	 epithelial	 phenotype,	 and	 hence,	 this	 may	 be	
driven	more	via	binding	 to	RAR-β,	or	perhaps	by	 less	 specific	
binding	 interactions	at	 the	higher	concentrations	required	 for	
EC19	to	be	effective.53	
The	 molecular	 basis	 for	 these	 observations	 has	 been	
explored	 and	 rationalized	 using	 comprehensive	 molecular	
modelling	 and	 docking	 experiments.	 This	 was	 initially	
conducted	 with	 the	 endogenous	 ATRA	 and	 9CRA	 to	 gain	
confidence	in	the	docking	procedure	and	its	results.	While	the	
overall	binding	pose	predicted	 for	 these	 retinoids	was	 similar	
to	those	determined	by	X-ray	crystallography,13,42	 for	ATRA	 in	
particular	 we	 observed	 a	 wide	 variety	 of	 possible	 binding	
conformations.	 Therefore,	 a	 clustering	 approach	 was	
employed	 that	 examined	 all	 of	 the	 docking	 solutions	 and	
allowed	 the	 determination	 of	 the	 most	 frequently	 sampled	
conformations.	The	distribution	of	conformations	agreed	with	
the	known	structures	of	the	respective	ligand	binding	pockets	
of	 the	 three	 RAR	 isotypes,	 with	 a	 broader	 range	 of	
conformations	 selected	 in	 the	 larger	 RARβ	 compared	 to	 the	
more	 elongated	 binding	 sites	 in	 RARα/γ.	 Overlaying	 the	 two	
most	 frequently	 sampled	 conformations	 (conformation	1	 and	
7)	 with	 the	 crystal	 structure	 of	 ATRA	 bound	 to	 RARγ	 may	
indicate	 that	 the	 pose	 determined	 by	 X-ray	 crystallography	
was	essentially	an	average	of	 the	two	 in-silico	 conformations,	
and	 allows	 us	 to	 conclude	 that	 rather	 than	 binding	 in	 one	
discrete	 conformation,	 ATRA	 likely	 binds	 in	 a	 range	 of	
conformations	that	 lie	very	close	to	each	other	 in	energy	and	
structure.	9CRA	also	exhibited	some	conformational	flexibility,	
but	 one	 binding	 conformation	 was	 clearly	 favoured	
(conformation	 1)	 due	 to	 the	 constraints	 of	 the	 RAR	 binding	
pocket,	 and	 indeed	 in	 RARα	 this	 was	 the	 sole	 binding	
conformation	due	to	a	steric	clash	between	the	gem-dimethyl	
group	 of	 conformation	 2	 with	 the	 RARα-specific	 residue	
Ser232.	 Interestingly,	 a	 recent	 study	 on	 an	 ATRA-receptor	
complex	 suggested	 that	 crystallography	 of	 small	 molecule-
protein	complexes	may	not	necessarily	lead	to	certainty	about	
the	actual	small	molecule	conformations	adopted,	particularly	
with	more	 conformationally	 flexible	 ligands.29,37	 An	 approach	
such	as	this	 in	which	all	possible	conformations	are	examined	
inside	and	outside	of	a	protein	environment	substantially	aids	
the	 fitting	 of	 novel	 ligands	 to	 crystallographic	 data.	 In	 turn,	
such	an	approach	will	further	aid	drug	design.	
These	observations	of	the	impacts	of	conformation	effects	
on	 RAR	 binding	 were	 then	 applied	 to	 analysing	 the	 possible	
interactions	 of	 EC23,	 EC19	 and	 their	 corresponding	 methyl	
esters,	 EC23Me	 and	 EC19Me	 with	 the	 RAR	 binding	 pockets.	
The	linear	structure	of	EC23	was	found	to	be	a	good	mimic	for	
the	predicted	binding	poses	of	ATRA,	and	further	examination	
showed	 that	 the	 hydrophobic	 region	 of	 EC23	 occupies	 both	
hydrophobic	 region	 positions	 of	 the	 two	 most	 frequently	
observed	 binding	 poses	 of	 ATRA.	 This	 ‘best	 of	 both	 worlds’	
binding	pose	is	one	likely	justification	for	the	increased	binding	
affinity	 exhibited	 by	 EC23	 over	 ATRA	 in	 the	 in	 vitro	 binding	
assay.	Furthermore,	the	significantly	increased	rigidity	of	EC23	
is	 likely	 to	 be	 another	 key	 reason	 for	 the	 strong	 binding	
characteristics	 of	 this	 synthetic	 retinoid	 versus	 ATRA.	 Indeed,	
one	 would	 anticipate	 that	 the	 highly	 restrained	 structure	 of	
EC23	would	experience	a	much-reduced	loss	of	configurational	
entropy	 on	 binding	 when	 compared	 to	 ATRA/9CRA.54	
Increased	 binding	 affinity	 from	 retinoids	 exhibiting	 increased	
rigidity	 has	 been	 reported	 for	 a	 number	 of	 other	 synthetic	
retinoids	 in	 both	 the	 RARs	 and	 RXRs.55,56	 EC19	 exhibited	
atypical	 retinoid	 binding	 according	 to	 simulation	 due	 to	 its	
meta-carboxylate	substituent.	This	resulted	in	the	sacrifice	of	a	
key	hydrogen	bond	 to	 the	polar	 cluster	 at	 the	bottom	of	 the	
pocket,	 and	 also	 served	 to	 give	 non-ideal	 hydrophobic	
interactions	around	the	hydrophobic	region	in	RARα	and	RARγ.	
However,	in	RARβ,	a	predicted	binding	pose	which	significantly	
strengthened	interactions	with	the	RARβ-specific	binding	cleft	
was	observed,	and	rationalized	the	specificity	of	EC19	towards	
RARβ	 in	 the	 in	 vitro	 assay.	 EC23Me	 and	 EC19Me	 generally	
exhibited	 reduced	 binding	 affinity	 compared	 to	 the	
corresponding	 acids	 due	 to	 the	 loss	 of	 hydrogen	 bonding	
interactions	at	the	polar	cluster,	and	also	due	to	a	movement	
of	 the	hydrophobic	 region	away	 from	 the	 center	of	 the	most	
hydrophobic	 part	 of	 the	 binding	 pocket.	 However,	 in	 RARα,	
docking	predicted	a	strong	hydrogen	bonding	contact	between	
EC19Me	 and	 the	 conserved	 serine	 amide	 NH	 protein	 and	 a	
movement	of	 the	hydrophobic	 region	up	 towards	H12,	which	
corroborated	the	significant	increase	in	binding	affinity	for	this	
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isotype	 to	 EC19Me	 in	 our	 experimental	 assay.	 This	 detailed	
level	of	structural	analysis,	 summarised	 in	Table	1,	provides	a	
relative	 ordering	 of	 effective	 binding	 of	 each	 ligand	 to	 the	
different	 RARs	 which	 was	 used	 to	 compare	 with	 receptor	
binding	 assays.	 The	 combination	of	molecular	modelling	with	
an	 experimental	 assay	 which	 is	 dependent	 on	 two	 separate	
ligand-receptor	 interactions	 strongly	 emphasises	 that	
biological	 activity	 is	 dependent	 on	 more	 than	 just	 ligand	
binding	 to	 the	 receptor	 LBD.		 Hence,	 with	 EC23,	 high	 LBD	
binding	affinity	does	not	always	translate	to	strong	coactivator	
recruitment	 and	 EC23	 exhibited	 substantially	 greater	 affinity	
for	 RARβ	 than	 the	 other	 retinoids,	 yet	 produced	 a	 poor	
coactivator	response.	On	the	other	hand,	EC19	exhibited	lower	
binding	 affinity	 but	 a	 higher	 coactivator	 response.	 Thus,	 the	
biological	 activity	 of	 natural	 and	 synthetic	 retinoids	 will	
depend	 on	 interactions	 at	 different	 levels	 for	 different	
receptor	 types,	 coupled	with	cell-type	variation	 in	abundance	
of	 different	 RAR	 types	 and	 the	 expression	 of	 coactivators	
which	may	determine	the	role	of	different	RAR	types	in	driving	
particular	biological	responses.		Overall	however,	the	receptor	
binding	 assays	 show	 broadly	 the	 same	 approximate	 overall	
rank	ordering	predicted	by	the	docking	studies	of	the	different	
ligands	 with	 each	 RAR,	 and	 most	 importantly,	 the	 overall	
approach	and	combination	of	tools	used	in	this	work,	in	which	
appropriate	analyses	of	ligand	conformations	in	the	context	of	
in	 silico	 docking	 along	 with	 biochemical	 assays,	 predicted	
the	effects	 of	 molecular	 interactions	 at	 different	 functional	
levels	 in	 a	 complimentary	 manner.	 Indeed,	 this	 approach	 is	
necessary	to	provide	 improved	 ligand	design	not	only	of	 new	
synthetic	 retinoids,	 but	more	widely	 in	 drug	 design,	where	 a	
fundamental	 level	 of	 understanding	 molecular	 interactions,	
including	 conformational	 effects	 and	 their	 impact	 upon	
binding,	 is	 required	 to	 enable	 both	 strongly	 binding	 ligands	
coupled	with	high	biological	activity.		
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